Weizmann's "Mitch" protein could unlock a new obesity treatment

Introduction: a protein nicknamed "Mitch" catches researchers' attention

A biological switch at the heart of our cells

A research team at the Weizmann Institute of Science in Israel has identified a protein that plays a key role in how our cells store or burn energy. This protein, affectionately nicknamed "Mitch," carries the scientific name MTCH2, an abbreviation referring to its precise location in the mitochondrial membrane, the structures that produce energy inside every cell.

The work, led by Professor Atan Gross in the institute's department of immunology and regenerative biology, shows that blocking this protein radically changes how human and animal cells use their fat reserves. It is this discovery that now opens a research path toward a future treatment for obesity.

A doctoral student at the center of the discovery

The study's lead researcher, Sabita Chourasia, a doctoral student in Professor Gross's lab, spent several years observing how removing Mitch altered the metabolic behavior of laboratory mice. Her work was later extended to human cells in collaboration with teams from the University of Pennsylvania and the University of Texas at San Antonio.

The results were published in the scientific journal EMBO Journal, a recognized publication in the field of molecular biology, which gives this discovery a scientific weight that goes beyond a simple media splash.

How mice without Mitch became resistant to obesity

More resilient animals with transformed metabolisms

When Sabita Chourasia's team genetically removed the Mitch protein from the muscles of laboratory mice, the results exceeded their initial expectations. The animals showed increased athletic capacity, better muscle fiber composition and structure, and a visibly accelerated metabolism compared to control mice.

Even more striking, these mice proved practically immune to weight gain, even when fed a high-fat diet specifically designed to induce obesity in normal rodents.

A heart more resistant to exertion

Exercise resistance tests also revealed better cardiac performance in mice lacking Mitch, a further sign that the absence of this protein deeply redirects how the body manages its available energy resources.

These animal observations convinced the team to push the experiment further into human cells, a necessary step before seriously considering a clinical application in humans.

What exactly happens in a human cell without Mitch

A mitochondrial network that fragments

In humans, researchers observed that blocking Mitch in cultured lab cells causes the normally interconnected mitochondrial network to fragment, with the organelles separating from one another. This phenomenon, called loss of mitochondrial fusion, fundamentally changes how the cell produces and manages its energy.

This fragmentation leads to a drop in efficiency in cellular energy production, placing the cell in a state researchers describe as permanent energy deprivation, even when nutrients are available in abundance.

A cell that revs up faster to compensate

To compensate for this deficit, cells lacking Mitch increase their cellular respiration and start burning more fat, carbohydrates and even amino acids to produce the energy they lack. This increased combustion translates into a marked drop in the membrane fats stored in the cell.

Researchers also noted a rise in fatty substances mobilized directly for energy production, a mechanism that partly explains why these cells seem unable to accumulate fat reserves normally.

A brake that also blocks the formation of new fat cells

Blocking the birth of adipocytes

Beyond its effect on already existing cells, removing Mitch also appears to slow the differentiation of precursor cells into new fat cells, a mechanism distinct from but complementary to the increased burning of existing reserves.

This double effect, on both the burning of stored fat and the formation of new fat tissue, is what makes this discovery particularly interesting to researchers who have studied the biological mechanisms of obesity for decades.

A path distinct from current treatments

Current obesity treatments, notably the GLP-1 agonists that have become very popular in recent years, act mainly on appetite and the feeling of fullness. Mitch's mechanism, by contrast, would act directly on how the cell manages and spends its energy, a complementary approach rather than a competing one.

This distinction could eventually open the door to combined treatments targeting both appetite and cellular metabolism itself, though this hypothesis remains, for now, in the realm of reasonable scientific speculation.

The words of the researchers behind the discovery

Sabita Chourasia describes an organism in a state of energy alert

In communications published by the Weizmann Institute, Sabita Chourasia explains that removing Mitch literally places the cell in a state of energy emergency, forcing it to draw on every available resource to maintain its basic functions despite the loss of efficiency of its fragmented mitochondria.

According to her, this constant metabolic stress state would explain why mice lacking Mitch in their muscles stay lean and active, even when fed a diet designed to fatten normal animals.

Professor Atan Gross calls it a "promising but early" lead

Professor Atan Gross, who oversees the lab behind this discovery, took care to place these results in their proper scientific context, noting that the path from cultured lab cells to a functional human treatment remains a long and uncertain journey, marked by numerous validation steps.

Gross nonetheless stresses that extending observations made in mice to human cells is a concrete step toward exploring a future obesity treatment, a milestone that is not guaranteed in the majority of similar basic discoveries.

Why this research matters in today's obesity context

A persistent global public health problem

Obesity remains one of the most persistent public health challenges worldwide, affecting hundreds of millions of people and contributing to a multitude of associated chronic diseases, including type 2 diabetes, cardiovascular disease and certain cancers.

Despite the arrival of recent pharmacological treatments targeting appetite, researchers continue to actively search for new biological mechanisms capable of acting as a complement or alternative, particularly for people who respond poorly to existing treatment options.

An approach that targets the cellular engine rather than the brain

What fundamentally sets the Mitch-related approach apart is that it attacks the cellular energy machinery directly rather than the hunger signals sent to the brain, a conceptual difference that could eventually benefit patients for whom current treatments aren't enough.

This path, however, remains entirely experimental at this stage, and no clinical trial in humans has yet been publicly announced by the Weizmann Institute's research team.

The limits and questions that remain unanswered

From the test tube to the whole human body

All the most spectacular observations of this study, notably protection against obesity and improved physical performance, were made in genetically modified mice, not in living humans under real-world conditions.

The experiments on human cells, while promising, were carried out in the lab on cultured cells, a situation that does not necessarily reproduce the complexity of a full human organism with its multiple interacting systems.

Potential side effects remain to be documented

Blocking a protein as central to mitochondrial function could carry as-yet-unknown side effects, particularly on organs heavily dependent on cellular energy production such as the heart, the brain or the liver, questions that only extensive further studies can clarify.

No public data currently allows for an assessment of the long-term safety of inhibiting Mitch in humans, which means any concrete pharmaceutical development would still require several more years of rigorous research.

What this discovery could change for future pharmaceutical research

A new target for the pharmaceutical industry

If future studies confirm the safety of partially inhibiting Mitch in humans, this protein could become a new therapeutic target for the pharmaceutical industry, on par with other metabolic mechanisms already exploited in treating diabetes or cardiovascular disease.

Major pharmaceutical companies are already closely watching mitochondrial mechanisms as a future avenue to complement existing treatments against obesity, a pharmaceutical market that has expanded rapidly since the arrival of GLP-1 agonists.

Funding for further work remains uncertain

As with most basic discoveries coming out of university labs, the future of Mitch research will largely depend on available funding for further preclinical studies, a step often underestimated by the general public but crucial to any real pharmaceutical development.

The Weizmann Institute has not publicly announced any partnership with a pharmaceutical company to pursue this line of research, which means the concrete next steps remain, for now, uncertain.

Conclusion: a serious lead, but still far from the pharmacy

A fundamental discovery worth attention

The discovery of the role of Mitch (MTCH2) in regulating mitochondrial fusion and cellular energy management represents a fundamental scientific advance worth noting, published in a respected peer-reviewed journal and led by a recognized team at the Weizmann Institute.

The successful transition from observations in mice to human cells in the lab is an encouraging step, without guaranteeing that a concrete treatment for obesity will emerge from it in the foreseeable future.

What to watch in the coming years

The logical next steps for this research would include more extensive preclinical trials, a better understanding of potential side effects, and eventually a first attempt at a clinical trial, a process that generally takes many years in the pharmaceutical field.

Until then, this discovery deserves to be followed with measured interest, neither dismissed as a mere publicity stunt nor prematurely presented as the long-awaited solution to obesity.

By Maxime Marquette, columnist

Columnist's transparency note

My stance on this research

I have no formal medical or biochemical training, and I approach this topic with the caution of a science communicator rather than the authority of an expert in the field. My role here is to make a complex scientific discovery accessible without exaggerating its scope or downplaying its real significance.

I have no personal or professional ties to the Weizmann Institute, Professor Atan Gross, or the researchers cited in this piece.

What I cannot claim

I cannot guarantee that a Mitch-based treatment will ever see the light of day, nor predict a realistic timeline for any potential human clinical trials. This analysis relies exclusively on available publications and official communications from the research team, without access to unpublished data.

Sources

Primary sources

Slimming Mitch — Weizmann Institute of Science, Wis-Wander, 2026

Study published in EMBO Journal — DOI 10.1038/s44318-024-00335-7

Health and medicine news — ScienceDaily

Secondary sources

Blocking energy control protein prevents fat accumulation — Technology Networks, 2026

Obesity immunity drug a step closer thanks to silencing Mitch — Matr, 2026

National Multiple Sclerosis Society — general health resource